- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Penn Medicine | Strategic Alliance Partners
.png?fit=crop&auto=format)
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer.
Collaboration is, and always has been, a cornerstone of Penn Medicine’s approach to groundbreaking research and quality care. Penn Medicine’s comprehensive cancer system includes the Abramson Cancer Center and Roberts Proton Therapy Center in Philadelphia, the Ann B. Barshinger Cancer Institute, Penn Medicine Princeton Cancer Center, and proton therapy center in Lancaster, the Penn Medicine | Virtua Health Proton Therapy Center in South New Jersy, and dozens of outpatient multispecialty care locations that stretch from the Susquehanna River in Pennsylvania to the New Jersey shore.
The Abramson Cancer Center has proudly been NCI-Designated Comprehensive since 1973. The Abramson Cancer Center is one of a select group of cancer centers in the country awarded the prestigious designation of Comprehensive Cancer Center by the National Cancer Institute. This status, which has been awarded to the Abramson Cancer Center continuously for the past 47 years, reflects our outstanding research, clinical services, education and information services and community outreach.
Connect with us:
Latest from Penn Medicine
Durvalumab Plus Concurrent Chemoradiotherapy Fails to Show PFS or OS Benefit in NSCLC
November 28, 2025
Article
Durvalumab administered with chemoradiotherapy rather than afterwards generated no significant improvement in PFS, OS, or ORR for patients with NSCLC.
Expert-Backed Roadmap Guides Outpatient Bispecific Antibody Use in Myeloma
September 14, 2025
Article
A roadmap shares guidelines for the safe administration of bispecific antibodies to patients with multiple myeloma in outpatient and community settings.
OncLive’s August Roundup of Key FDA Approvals in Oncology: 3 Decisions to Know
September 02, 2025
Article
Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.
Five Under 5: Top Oncology Videos for the Week of 8/24
August 31, 2025
Article
The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.
Dr Haas on Evolutions in Clinical Trial Design in the RCC Treatment Paradigm
August 04, 2025
Video
Naomi B. Haas, MD, discusses previously conducted trials that supported the initiation of the KEYNOTE-564 trial of adjuvant pembrolizumab in RCC.
Novel Treatment Approaches Under Investigation in ROS1+ NSCLC
May 30, 2025
Video
Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on novel approaches being investigated in ROS1-positive non–small cell lung cancer.
Another FDA-Approved Option? The Potential Role for Taletrectinib in ROS1+ NSCLC
May 30, 2025
Video
Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on how FDA approval of taletrectinib would affect ROS1-positive non–small cell lung cancer management.
Pooled Data for Taletrectinib in ROS1+ NSCLC
May 30, 2025
Video
Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss data for taletrectinib in ROS1-positive non–small cell lung cancer.
Addressing CNS Involvement in ROS1+ NSCLC
May 30, 2025
Video
Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss CNS involvement in ROS1-positive non–small cell lung cancer.
Selecting a TKI in ROS1+ NSCLC Management
May 30, 2025
Video
Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss TKI selection in ROS1-positive non–small cell lung cancer.
Treatment Sequencing Decisions in ROS1+ NSCLC
May 30, 2025
Video
Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss treatment sequencing in ROS1-positive non–small cell lung cancer.
The Prevalence of ROS1 Fusions in Advanced NSCLC
May 30, 2025
Video
Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss the prevalence of ROS1 fusions in non–small cell lung cancer.
Five Under 5: Top Oncology Videos for the Week of 5/18
May 25, 2025
Article
The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.
Lung Cancer Experts Highlight the Significance and Limitations of ADCs
April 30, 2025
Video
Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.
Dr Garfall on the Inclusion Criteria for a Study Evaluating Ide-Cel in Myeloma After Suboptimal Transplant/Maintenance Response
March 19, 2025
Video
Alfred L. Garfall, MD, describes the inclusion criteria for a phase 2 study evaluating ide-cel as first-line maintenance in multiple myeloma.
Immunotherapy May Boost KRAS-Targeted Therapy in Pancreatic Cancer
March 19, 2025
Article
A preclinical study offers a foundation for a combination strategy in future clinical trials for KRAS mutations.
Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer
March 16, 2025
Article
Patients with cyclin E1–positive platinum-resistant ovarian cancer experienced a greater response to azenosertib vs the overall DENALI population.
Dr Ruella on the Importance of Clinical Trial and Treatment Accessibility for Myeloma
March 10, 2025
Video
Marco Ruella, MD, discusses ways to develop accessible cancer treatments to more greatly benefit diverse populations of patients with multiple myeloma.
Text Message Tool Addresses "Time Toxicity" for Patients With Cancer
February 27, 2025
Article
In pilot study, patients saved over an hour of time at every treatment visit.
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
February 18, 2025
Article
Tara C. Mitchell, MD, discusses considerations and lingering questions regarding pre- and post-operative management strategies in stage IIB/IIIC melanoma.